New materials to prevent infections in intravenous catheters
Official title: Novel Polymer Additives for Infection Control Intravenous Catheters
Funded at Halomine, INC. · NIH-10914548 · Data updated 2026-11-12
This study is testing a new material for central venous catheters that helps prevent infections, making it safer for patients in intensive care units.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Halomine, INC. NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $295,203 |
| NIH project number | 1R43HL172530-01A1 |
| Project ID | NIH-10914548 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who require central venous catheters, particularly those in intensive care settings.
✕Less likely to help
Patients who do not require intravenous catheters or those with existing infections may not benefit from this research.
What this research studies
This research focuses on developing a novel polymer additive that combines antimicrobial and antifouling properties to reduce infections associated with central venous catheters (CVCs). By optimizing the blending of this additive with thermoplastic polyurethane, the goal is to create a safer and more effective catheter material. The research aims to address the significant issue of central line-associated bloodstream infections (CLABSIs), which affect many patients in intensive care units. Patients may benefit from this innovative approach that seeks to enhance catheter safety and reduce infection rates.
Why it matters
Potential benefit: If successful, this research could significantly lower the incidence of catheter-related infections, improving patient safety and outcomes.
How similar studies have gone: While there are existing approaches to reduce catheter infections, this specific combination of antimicrobial and antifouling properties is novel and has not been extensively tested.
Where this research is happening
-
Halomine, INC.
Ithaca, United States Active
Researchers
- Principal investigator: Ozkan, Ekrem — Halomine, INC.
- Study coordinator: Ozkan, Ekrem
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.